Simulation output

Costs

This output panel depicts some of the costs which will accumulate during an epidemic.

	Work loss (red curve) displays the cumulative costs related to work loss caused by influenza. Note, that this curve shows only the work loss costs which are directly due to sickness, but does not consider reasons which indirectly contribute to the work loss (e.g. taking care of sick people, closing of factories, break-down of public transportation etc.).
	Outpatients (dark blue curve) displays the cumulative costs caused by doctoral visits of influenza patients. Note, that this curve only considers influenza patients with severe symptoms and assumes exactly one doctoral visit per patient.
	Hospitalizations (green curve) displays the cumulative costs caused by hospitalizations.
	Antivirals (yellow curve) displays the cumulative costs of antiviral treatment.
	Total (magenta curve) displays the sum of the above mentioned cumulative costs.

	The cumulative curve of Work loss costs mainly depends on the fraction of infections which lead to severe disease, on the corresponding duration of sickness and convalescence and on the average costs for each week of work loss. As the duration of disease can be reduced by antiviral treatment, the cumulative work loss can be reduced by treatment.
	The cumulative curve of costs caused by Outpatients mainly depends on the fraction of infections which lead to severe disease, on the time when such cases seek medical help and on the average costs for one outpatient visit.
	The cumulative curve of costs caused by Hospitalizations mainly depends on the fraction of infections which need hospitalization (which also depends on the fraction of severe cases) and on the average costs for one hospitalization. The fraction of hospitalizations can be reduced by antiviral treatment, so that the cumulative costs caused by hospitalizations can be reduced by treatment.
	The cumulative curve costs caused by distribution of Antivirals mainly depends on the treatment of severe and extremely severe cases, on the availability of antiviral drugs and on the average costs per antiviral treatment course.